Volpara Health Technologies Limited, founded in 2009 and headquartered in Wellington, New Zealand, specializes in developing advanced software solutions for medical imaging analysis, primarily focused on breast cancer screening. Their extensive product line includes Volpara Analytics, designed to optimize breast cancer screening workflows, and Volpara Live, which delivers immediate, patient-specific feedback on image quality. They also offer the Volpara Patient Hub, a customizable platform for mammography reporting and patient communication. Integrated with Patient Hub, Volpara Risk utilizes TC8 to calculate a patient's risk of developing breast cancer, complemented by Volpara Risk Pathways, a program for identifying and managing high-risk individuals. The Volpara Scorecard provides crucial insights into patient breast density and risk, facilitating informed clinical decisions and early detection. All Volpara software products are powered by Volpara Science, an underlying AI-driven technology. The company further provides specialized clinical functions such as TruDensity for precise breast density assessment; TruPGMI, which employs artificial intelligence to objectively evaluate patient positioning and image quality; TruPressure, designed to optimize compression during imaging for superior image quality, minimal radiation, and enhanced patient comfort; and TruRadDose, which analyzes radiation dosage relative to breast density. Beyond breast imaging, Volpara offers Volpara Lung, a patient management software that streamlines the lung screening process. Volpara Health Technologies maintains a broad international presence, operating across North America, Asia Pacific, Europe, the Middle East, and Africa, and holds a strategic alliance with RevealDx.